Cure My Disease

Don't miss your cure!

 Log in / Sign up

New drug shows promise for improving walking in adults with spinal muscular atrophy

NCT ID NCT05794139

Completed Symptom relief Sponsor: NMD Pharma A/S Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tested an experimental drug called NMD670 in 52 adults with type 3 spinal muscular atrophy who can still walk. The goal was to see if the drug helps them walk farther in 6 minutes and improves muscle strength compared to a placebo. The trial is now complete, and results will show whether NMD670 can ease symptoms of this muscle-weakening condition.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for SPINAL MUSCULAR ATROPHY are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

spinal muscular atrophy spinal muscular atrophy, type III

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

SPINAL MUSCULAR ATROPHY

Contacts and locations

Locations

  • AOU Città della Salute e della Scienza di Torino

    Torino, Italy

  • Aarhus Universitetshospital, Neurologisk Afdeling

    Aarhus, Denmark

  • CHR de la Citadelle - Neurologie

    Liège, Belgium

  • Charite - Campus Virchow-Klinikum (CVK)

    Berlin, Germany

  • Genge Partners Inc.

    Montreal, Canada

  • Heritage Medical Research Clinic

    Calgary, Canada

  • Hospital Materno Infantil La Paz

    Madrid, Spain

  • Hospital Universitari Vall D Hebron

    Barcelona, Spain

  • Hospital Universitario y Politécnico La Fe

    Valencia, Spain

  • Istituto Giannina Gaslini, IRCCS

    Genova, Italy

  • Istituto Neurologico C. Besta, Fondazione IRCCS

    Milan, Italy

  • Neurology Rare Disease Center

    Denton, Texas, 76208, United States

  • Ospedale Niguarda, ASST Grande Ospedale Metropolitano Niguarda

    Milan, Italy

  • Rare Disease Research - Raleigh-Durham

    Hillsborough, North Carolina, 27278, United States

  • Rigshospitalet - Neurologisk Afdeling

    Copenhagen, Denmark

  • Roy Blunt NextGen Precision Health Institute

    Columbia, Missouri, 65212, United States

  • Stanford University Medical Center

    Palo Alto, California, 94304, United States

  • The Johns Hopkins Medicine, Spinal Muscular Atrophy Center

    Baltimore, Maryland, 21287, United States

  • The Ohio State University Wexner Medical Center

    Columbus, Ohio, 43210, United States

  • UCLA David Geffen School Of Medicine - Neurology

    Los Angeles, California, 90095, United States

  • UZ Leuven - Neurochirurgie Campus Gasthuisberg

    Leuven, Belgium

  • Universitair Medisch Centrum Utrecht, locatie Academisch Zie - Neurology

    Utrecht, Netherlands

  • University of Kansas Medical Center

    Kansas City, Kansas, 66160, United States

  • Universitätsklinikum Essen - Klinik Für Neurologie

    Essen, Germany

  • Washington University School of Medicine

    St Louis, Missouri, 63110, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.